Why Shares of Stoke Therapeutics Plummeted in September
After top performance in August, the biotech was hit hard.
After top performance in August, the biotech was hit hard.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?